Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy.

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound ...

New targeted therapies allow for the treatment of a disease that is already the fifth leading cause of fatal tumors globally ...

The University of Virginia Medical Center is not just one of Newsweek’s top 50 hospitals in the country (and No. 1 in the ...

Chemoimmunotherapy offers greater benefits than harms as first-line treatment for older patients with NSCLC, data suggest.

It's been a challenging year for NovoCure (NASDAQ: NVCR), an oncology-focused biotech. NovoCure's average price target on ...

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...